Skip to Content
Søk Menu

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

Charlotte Haslund, MD, chief oncologist at the Department of Oncology, Aalborg University Hospital, specializing in gynecological cancer, presented highlights and Danish perspectives on ovarian cancer at the Danish Evening at ESMO 2024.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynekologisk cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungcancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungcancer
Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Levercancer Play the Video 04:57

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanom
Back to top